---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-003023"
form_type: "8-K"
ticker: "NTRB"
cik: "0001676047"
company_name: "NutriBand Inc."
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:35:05.763707+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch

## Summary
- Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.
- Agreement replaces prior feasibility deal; moves AVERSA Fentanyl toward NDA filing.
- AVERSA Fentanyl estimated peak annual US sales $80M-$200M per Health Advances 2022 market analysis.

## SEC filing metadata
- accession: 0001213900-24-003023
- form_type: 8-K
- ticker: NTRB
- cik: 0001676047
- company_name: NutriBand Inc.
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676047/000121390024003023/0001213900-24-003023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676047/000121390024003023/ea191528-8k_nutriband.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-003023
- JSON: https://secwatch.observer/filing/0001213900-24-003023.json
- Plain text: https://secwatch.observer/filing/0001213900-24-003023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.